Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 13/20 | 0.56 |
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA4 | P22748 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046408 | 0.97 | PTGER2 (0.55) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5049387 | 0.90 | PTGER2 (0.51) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL4946002 | 0.89 | CNR2 (0.65) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5043213 | 0.87 | PTGER2 (0.51) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5046567 | 0.86 | PTGER2 (0.58) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL27664512 | 0.85 | CNR2 (0.52) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5043574 | 0.84 | CA12 (0.60) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5050520 | 0.84 | TAS2R14 (0.56) | PTGER2CNR2 | |
| SCHEMBL5048052 | 0.84 | CNR2 (0.75) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5048023 | 0.83 | CA12 (0.64) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | claimed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | claimed |
| CN-1599605-A | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PFIZER PROD INC (US) | 2005-03-23 | — | — | CN | claimed |
| EP-1448182-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP 2 RECEPTOR SELECTIVE AGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | DUMONT FRANCIS (US) | 2003-09-04 | — | — | US | claimed |
| WO-2003045371-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP2 RECEPTOR SELECTIVE AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | claimed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | claimed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1697356-B1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PROD INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PFIZER INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| CN-1859903-A | Use of EP2 selective receptor agonists in medical treatment | PFIZER PROD INC (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1697356-A1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | Pfizer Products Incorporated (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-20010056060-A1 | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | CAMERON KIMBERLY O (US) | 2001-12-27 | — | — | US | disclosed |
| EP-1121939-A2 | Treatment of osteoporosis with EP2/EP4 receptor selective agonists | Pfizer Products Inc. (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PDE12, PDE2A, PDE3A | PTGER2 83/4885CA12 3632/4885CA1 3745/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | PTGER2 4/4885CA12 4780/4885CA1 4650/4885 |
| US-20010056060-A1 | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | PTGER2, PTGER1, PTGER4 | PTGER2 1/4885CA12 4848/4885CA1 4835/4885 |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PTGER2, PTGER1, PTGFR | PTGER2 1/4885CA12 3614/4885CA1 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.